Shanghai-based contract research, development, and manufacturing organization (CRDMO) Ribobay Pharma has announced plans to commence offering GMP-level CRDMO services for oligonucleotide manufacturing in the near future. In collaboration with its spin-off company, General Biol (Anhui) Co., Ltd, the companies aim to provide access to Cytiva’s FlexFactory platform for oligo manufacturing. The new facility located in Anhui province is projected to become operational starting from June this year.
Ribobay is strategically positioning itself to capitalize on the growing demand for oligonucleotide drug manufacturing. With an estimated 1,500 oligo drugs currently in development globally, the applications cover a broad spectrum of conditions, including hyperlipidemia, hepatitis B, diabetes, and obesity.- Flcube.com
